1. Valeant started the year by selling off $2.1 billion in assets.
2. The company has $30.4 billion in lingering debt. Through selling off strategic assets, however, it avoided paying additional interest on a bond.
3. As of Feb. 24, 2017, Valeant shares were trading at $16.24 per share. The company has a 52-week high of $86.50 and a 52-week low of $13.
More articles on gastroenterology/endoscopy:
LifeBond enrolling patients in LifeSeal surgical sealant study: 4 key notes
GI leader to know: Dr. Sam Moussa of Adobe Gastroenterology
5 ways CMS changes are affecting reimbursement for ASCs, anesthesia practices and providers
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
